Streetbeat News

TELO

Telomir Pharmaceuticals Inc

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

5.10

Mkt cap

136M

Volume

305K

High

5.23

P/E Ratio

-8.18

52-wk high

9.39

Low

4.50

Div yield

N/A

52-wk low

3.11

Telomir Pharmaceuticals announced that its drug Telomir-1 significantly reduces tumor size and suppresses cancer progression in a prostate cancer animal model. The drug also neutralizes chemotherapy toxicity when combined with Paclitaxel.

Portfolio Pulse from

March 19, 2025 | 12:15 pm

Portfolio Pulse from

March 19, 2025 | 12:15 pm

Telomir Pharmaceuticals announced that its product, Telomir-1, has shown promising preclinical results in reversing calcium dysregulation, oxidative stress, and preserving cellular integrity in human cell lines. This breakthrough could have significant implications for age-reversal science.

Portfolio Pulse from

February 26, 2025 | 1:15 pm

Telomir Pharmaceuticals has achieved a breakthrough in stabilizing silver ions, potentially unlocking a multi-billion-dollar market in medical applications.

Portfolio Pulse from

February 21, 2025 | 1:15 pm

Telomir Pharmaceuticals has announced promising results from its copper binding studies with Telomir-1, which could be used to treat Wilson's disease and other copper-related disorders.

Portfolio Pulse from

December 23, 2024 | 12:45 pm

Telomir Pharmaceuticals announced preclinical results showing that their compound, Telomir-1, can reverse aging and increase longevity in model organisms. This breakthrough positions Telomir as a leader in age-reversal science.

Portfolio Pulse from

November 21, 2024 | 12:15 pm

Nikola Corporation's shares fell by 10.4% after announcing a securities purchase agreement and a mixed shelf offering. Other stocks like Alzamend Neuro and Virax Biolabs saw significant gains, while Liquidia Corporation and Theriva Biologics experienced notable declines.

Portfolio Pulse from Avi Kapoor

August 19, 2024 | 5:37 pm

Telomir Pharmaceuticals announced the passing of its Chairman and CEO, Christopher Chapman, Jr., M.D. Erez Aminov, currently CEO of MIRA Pharmaceuticals, has been appointed as the new CEO and Chairman of Telomir. The company also announced changes to its Board of Directors.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:40 pm

Telomir Pharmaceuticals (NASDAQ:TELO) has been added to the Russell 3000 and Russell Microcap Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 12:34 pm

Telomir Pharmaceuticals has commenced a study to evaluate the safety of Telomir-1 when administered orally to geriatric Beagle dogs for 63 consecutive days. The study began on May 28th, and initial dosing was well-tolerated by all animals. The data will explore the potential for treating age-related conditions.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 12:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.